| ID Source | ID |
|---|---|
| PubMed CID | 11957621 |
| CHEMBL ID | 1448326 |
| SCHEMBL ID | 347598 |
| MeSH ID | M0307738 |
| Synonym |
|---|
| 5-(2-aminoethyl)guaiacol hydrochloride |
| einecs 216-035-1 |
| 95hil684p5 , |
| 5-(2-aminoethyl)guaiacol hcl |
| 3-methoxy-4-hydroxyphenylethylamine hydrochloride |
| nsc 172190 |
| unii-95hil684p5 |
| AKOS015848662 |
| EU-0100796 |
| 3-methoxytyramine hydrochloride, >=95.5%, crystalline |
| homovanillylamine hydrochloride |
| 1477-68-5 |
| nsc172190 |
| nsc-172190 |
| 3-methoxytyramine hydrochloride, 96% |
| 3-methoxy-4-hydroxyphenethylamine hydrochloride |
| NCGC00094131-01 |
| 3-methoxytyramine hydrochloride |
| M-3581 |
| smr001230761 |
| MLS002153361 |
| 3-methoxytyramine hydrochloride, >=99.0% (at) |
| M 4251 |
| 3-o-methyldopamine hydrochloride |
| EN300-77642 |
| 3-o-methyldopamine hydrochloride pa |
| 3-methoxytyramine, hydrochloride |
| 4-(2-aminoethyl)-2-methoxyphenol hydrochloride , |
| 3-methoxytyramine hcl |
| 4-(2-amino-ethyl)-2-methoxy phenol hydrochloride |
| 4-hydroxy-3-methoxyphenylethylamine hydrochloride |
| 3-methoxy-4-hydroxy-phenylethylamine hydrochloride |
| 4-hydroxy-3-methoxyphenethylamine hydrochloride |
| 2-(4-hydroxy-3-methoxyphenyl)ethylamine hydrochloride |
| S3370 |
| FT-0671206 |
| FT-0633584 |
| SCHEMBL347598 |
| 4-(2-amino-ethyl)-2-methoxyphenol hydrochloride |
| 2-(4-hydroxy-3-methoxy-phenyl)-ethylamine hydrochloride |
| AWRIOTVUTPLWLF-UHFFFAOYSA-N |
| 2-(4-hydroxy-3-methoxyphenyl)-ethylamine hydrochloride |
| 4-(2-amino-ethyl)-2-methoxy-phenol hydrochloride |
| guaiacol, 4-(2-aminoethyl)-, hydrochloride |
| 4-hydroxy-3-methoxy-.beta.-phenethylamine hydrochloride |
| phenol, 4-(2-aminoethyl)-2-methoxy-, hydrochloride (1:1) |
| 2-methoxytyramine hydrochloride |
| CHEMBL1448326 |
| 3-methoxy-p-tyramine hydrochloride |
| CS-8045 |
| 3-methoxytyramine (hydrochloride) |
| HY-103638 |
| mfcd00012902 |
| DTXSID40163784 |
| 4-(2-aminoethyl)-2-methoxyphenol;hydrochloride |
| phenol, 4-(2-aminoethyl)-2-methoxy-, hydrochloride |
| J-516087 |
| CS-W008266 |
| 3-methoxytyramine hydrochloride, analytical standard |
| Z1268152336 |
| 3-methoxytyramine hydrochloride, 1.0 mg/ml in methanol (as free base), certified reference material |
| sr-01000075367 |
| SR-01000075367-1 |
| 3-methoxytyramine, hcl |
| 3-mt hcl;3-o-methyldopamine hcl |
| 4-(2-aminoethyl)-2-methoxyphenol hcl |
| 3-o-methyldopamine hydrochloride; 3-methoxy tyramine hcl |
| DS-6547 |
| 4-hydroxy-3-methoxyphenethylamine hcl |
| AMY4299 |
| Q27271794 |
| 3-o-methyldopamine hydrochloride 100 microg/ml in acetonitrile:methanol |
| 3-o-methyl dopamine hydrochloride |
| 3-o-methyl dopamine hydrochloride) |
| SY062385 |
| PD040932 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLS protein | Homo sapiens (human) | Potency | 11.2202 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 5.0119 | 4.4668 | 18.3916 | 35.4813 | AID2107 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 11.2202 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| geminin | Homo sapiens (human) | Potency | 0.7308 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 4.4668 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.0050 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| trace amine-associated receptor 1 | Homo sapiens (human) | IC50 (µMol) | 21.6140 | 0.1571 | 3.8257 | 9.3940 | AID686984 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| trace amine-associated receptor 1 | Homo sapiens (human) | EC50 (µMol) | 2.4020 | 0.0685 | 2.1184 | 9.9700 | AID686985 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||